Page last updated: 2024-08-21

pyrazines and azd 6244

pyrazines has been researched along with azd 6244 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Anderson, KC; Burger, P; Chauhan, D; Fulciniti, M; Ghobrial, IM; Hideshima, T; Leiba, M; Li, XF; Morrison, A; Munshi, NC; Podar, K; Richardson, P; Rumizen, M; Song, W; Tai, YT; Tassone, P	1
Eckhardt, SG; Flanigan, SA; Kachaeva, MI; Kulikowski, GN; Leong, S; McManus, MC; Newton, TP; Pitts, TM; Selby, HM; Spreafico, A; Tan, AC; Tentler, JJ	1
Ahn, MJ; Frigault, MM; Ghiorghiu, D; Goto, K; Horn, L; Kim, SW; Mann, H; Ohe, Y; Oxnard, GR; Ramalingam, SS; Saka, H; Thress, KS; Vishwanathan, K; Yang, JC; Yu, H	1

Trials

2 trial(s) available for pyrazines and azd 6244

Article	Year
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood, 2007, Sep-01, Volume: 110, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Differentiation; Cell Proliferation; Cell Survival; Cytotoxins; Dexamethasone; Dose-Response Relationship, Drug; Interleukin-6; Lenalidomide; Ligands; Macrophage Colony-Stimulating Factor; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Phosphorylcholine; Pyrazines; RANK Ligand; Stromal Cells; Thalidomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2007
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:4 Topics: Acrylamides; Aniline Compounds; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazines; Triazines	2020

Article

Year

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

Blood, 2007, Sep-01, Volume: 110, Issue:5

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Differentiation; Cell Proliferation; Cell Survival; Cytotoxins; Dexamethasone; Dose-Response Relationship, Drug; Interleukin-6; Lenalidomide; Ligands; Macrophage Colony-Stimulating Factor; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Phosphorylcholine; Pyrazines; RANK Ligand; Stromal Cells; Thalidomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2007

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:4

Topics: Acrylamides; Aniline Compounds; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazines; Triazines

2020

Other Studies

1 other study(ies) available for pyrazines and azd 6244

Article	Year
Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Nov-15, Volume: 19, Issue:22 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Butadienes; Caspase 3; Caspase 7; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imidazoles; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Nude; Neoplasm Transplantation; Nitriles; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Transplantation, Heterologous	2013

Article

Year

Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Nov-15, Volume: 19, Issue:22

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Butadienes; Caspase 3; Caspase 7; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imidazoles; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Nude; Neoplasm Transplantation; Nitriles; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Transplantation, Heterologous

2013